Provided by Tiger Trade Technology Pte. Ltd.

Neumora Therapeutics, Inc.

1.33
-0.0600-4.32%
Post-market: 1.350.0200+1.50%19:13 EDT
Volume:633.05K
Turnover:855.87K
Market Cap:250.04M
PE:-1.09
High:1.45
Open:1.40
Low:1.32
Close:1.39
52wk High:3.65
52wk Low:0.8302
Shares:188.00M
Float Shares:116.00M
Volume Ratio:0.93
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2237
EPS(LYR):-1.4501
ROE:-187.11%
ROA:-73.85%
PB:5.62
PE(LYR):-0.92

Loading ...

Neumora Therapeutics Price Target Maintained With a $8.00/Share by Needham

Dow Jones
·
Mar 31

Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access

TIPRANKS
·
Mar 31

Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)

TIPRANKS
·
Mar 30

Neumora Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 30

Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate

Benzinga Earnings
·
Mar 30

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

TIPRANKS
·
Mar 30

Neumora FY25 net loss narrows to $237 million; cash drops to $183 million

Reuters
·
Mar 30

Neumora Therapeutics Inc: NOW Expects to Bring Nmra-215 Into Clinic in Q1 of 2027

THOMSON REUTERS
·
Mar 30

Press Release: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Neumora publishes corporate presentation outlining neuroscience pipeline and upcoming clinical milestones

Reuters
·
Mar 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

Neumora Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Mar 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 27

Neumora Therapeutics to report Q4 and full-year 2025 financial results in conference call and webcast

Reuters
·
Mar 16

LB Pharmaceuticals appoints Robert Lenz to board

Reuters
·
Mar 09